XENT
$15.50
Intersect Ent
($.10)
(.64%)
XENT
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.44)
Revenue:  $21.74 Mil
Monday
Nov 2
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when XENT reports earnings?
Beat
Meet
Miss

Where is XENT's stock price going from here?
Up
Flat
Down
Stock chart of XENT
Analysts
Summary of analysts' recommendations for XENT
Score
Grade
Pivots
Resistance
$16.39
$16.09
$15.79

$15.49

Support
$15.20
$14.90
$14.60
Tweet
Growth
Description
Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.
Peers
StrykerBoston ScientificBaxter InternationalBecton, DickinsonAbbottWatersIntegra LifeSciences Holdings3MTeleflexCardiovascular Systems